Region Sjaelland
- Address
- lock Available on a paid plan
Cardiovascular Diseases
The Hjertemedicinsk Forskningsenhed in Holbæk conducts studies aimed at improving treatment and prevention of heart‑related conditions. Trials explore new therapies for atherosclerotic cardiovascular disease, strategies to reduce risk of stroke in patients with atrial fibrillation, and interventions during in‑hospital cardiac arrest. The goal is to evaluate effectiveness of innovative drugs and emergency measures to lower mortality and complications.
- Evaluation of novel anticoagulant asundexian versus standard therapy
- Assessment of lipoprotein‑targeting agent olpasiran for reducing cardiovascular events
- Investigation of sodium bicarbonate use in cardiac arrest resuscitation
- Study of outcomes after coronary events in ASCVD patients
Researchers at the site collaborate with local hospitals to bring cutting‑edge cardiovascular care to patients across Denmark.
Nutritional and Metabolic Diseases
At the same department, investigators focus on weight management and metabolic health, testing new approaches for children with obesity and adults struggling with excess weight. One study examines the impact of a weekly injection of semaglutide combined with lifestyle changes on body‑mass reduction in young patients. The overarching aim is to identify safe and effective options to combat obesity and its related complications.
- Semaglutide therapy for pediatric obesity
- Lifestyle‑enhanced pharmacologic weight loss programs
- Monitoring of metabolic markers during treatment
- Strategies to prevent progression to cardiovascular disease
The clinic’s multidisciplinary team integrates nutrition, endocrinology, and cardiology expertise to support participants throughout the trials.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 22 therapeutic areas and 15 of 305 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 294 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 41 by active trials.
- 1Zealand University Hospital11active
lock +40 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Zealand University Hospital13trials
lock +27 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 111 other sites in Denmark
Therapeutic Area Benchmark — Denmark
Select a therapeutic area to compare against other sites in Denmark.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Denmark
Market Share
Country: Denmark
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Region Sjaelland
lock Showing 1 of 133 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of GSK3862995B in Participants with Bronchiectasis | GSK PLC | Phase II | Recruiting | Mar 2026 | — |
IMP list
lock Showing 1 of 305 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Sodium Chloride | 11 | Unknown | 2020-08-19 | 2026-05-30 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.